Jean-Marie Martinez

Population pharmacokinetic analysis of fexofenadine in Japanese pediatric patients

S. Khier, D. Fabre, Jean-Marie Martinez, 2014, Journal of Pharmacokinetics and Pharmacodynamics.

Population Pharmacokinetic/Pharmacodynamic Analysis of Alirocumab in Healthy Volunteers or Hypercholesterolemic Subjects Using an Indirect Response Model to Predict Low-Density Lipoprotein Cholesterol Lowering: Support for a Biologics License Application Submission: Part II

X. Nicolas, N. Djebli, D. Fabre, 2018, Clinical Pharmacokinetics.

Population Pharmacokinetic Analysis of Alirocumab in Healthy Volunteers or Hypercholesterolemic Subjects Using a Michaelis–Menten Approximation of a Target-Mediated Drug Disposition Model—Support for a Biologics License Application Submission: Part I

D. Fabre, F. Hurbin, Jean-Marie Martinez, 2018, Clinical Pharmacokinetics.

Population pharmacokinetic analysis of fexofenadine in Japanese pediatric patients

S. Khier, D. Fabre, Jean-Marie Martinez, 2014, Journal of Pharmacokinetics and Pharmacodynamics.

Evaluation of the Switch From Amiodarone to Dronedarone in Patients With Atrial Fibrillation: Results of the ARTEMIS AF Studies

Deepak L. Bhatt, J. Le Heuzey, A. Camm, 2020, Journal of cardiovascular pharmacology and therapeutics.

Target-Mediated Drug Disposition Population Pharmacokinetics Model of Alirocumab in Healthy Volunteers and Patients: Pooled Analysis of Randomized Phase I/II/III Studies

S. Khier, N. Djebli, D. Fabre, 2017, Clinical Pharmacokinetics.

Population pharmacokinetic modeling and dosing simulation of avalglucosidase alfa for selecting alternative dosing regimen in pediatric patients with late-onset pompe disease

P. Miossec, D. Fabre, F. Hurbin, 2023, Journal of Pharmacokinetics and Pharmacodynamics.

Population Pharmacokinetic Modeling and Determination of Individual Exposure to Avalglucosidase Alfa in Adolescent and Adult Patients With Late-Onset Pompe Disease: Analysis of Pooled Data From Phase I to III Clinical Trials

D. Fabre, F. Hurbin, G. Tuffal, 2023, Therapeutic drug monitoring.